You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

Switch to the US site

News

Interim Report January – June 2017

Press Release July 17, 2017Gothenburg, Sweden

Interim Report January – June 2017

April – June 2017 in brief

  •  Order intake increased by 1.1% to SEK 7,539 M (7,460). The order intake declined organically by 3.8%.  
  •  Net sales rose by 4.5% to SEK 7,241 M (6,927). Net sales decreased organically by 0.5%. 
  •  Cash flow from operations declined 51.8% to SEK 223 M (463). The cash conversion amounted to 29.1% (44.7). 
  •  EBITA 1* increased 9.6% to SEK 864 M (788). 
  •  Restructuring and integration costs amounted to SEK 524 M (133), of which SEK 488 M comprised a provision for improvements in Hechingen in accordance with the Consent Decree with the FDA. 
  •  Profit after financial items fell to SEK 9 M (311). 
  •  Earnings per share declined to SEK 0.01 (0.93). 
  •  Savings of slightly more than SEK 100 M were achieved via the Big 5 efficiency-enhancement program.  
  •  Plan for guaranteed rights issue of approximately SEK 4 billion.  
  •  A minor acquisition within Surgical Workflows 
  •  After the quarter: Lars Sandström was appointed CFO and the notice of the EGM for the proposed Rights Issue was published.

January – June 2017 in brief

  •  Order intake increased by 2.8% to SEK 14,788 M (14,384). The order intake declined organically by 1.6%.  
  •  Net sales increased by 4.5% to SEK 13,905 M (13,304), corresponding to an organic change of 0.0%. 
  •  Cash flow from operations fell by 6.2% to SEK 1,091 M (1,163). The cash conversion amounted to 55.3% (59.2). 
  •  EBITA 1* improved by 19.5% to SEK 1,682 M (1,408). 
  •  Restructuring and integration costs amounted to SEK 620 M (260).  
  •  Profit after financial items decreased to SEK 392 M (468). 
  •  Earnings per share declined to SEK 1.17 (1.39). 
  •  Savings of slightly more than SEK 200 M were achieved via the Big 5 efficiency-enhancement program. 

Financial summary 

Quarter 2 2017  Quarter 2 
2016 
Jan-Jun 
2017  
Jan-Jun
2016  
Rolling  
12M  
Full year
2016 
Order intake,   SEK M  7,539  7,460  14,788  14,384  30,546  30,142 
Net sales, SEK   M  7,241  6,927  13,905  13,304  30,357  29,756 
Gross profit,   SEK M  3,449  3,167  6,744  6,178  14,406  13,840 
Gross margin, %  47.6  45.7  48.5  46.4  47.5  46.5 
EBITA 1*, SEK   M  864  788  1,682  1,408  4,615  4,341 
EBITA 1*   margin, %  11.9  11.4  12.1  10.6  15.2  14.6 
Operating   profit (EBIT), SEK M  162  473  702  789  2,200  2,287 
Profit after   financial items, SEK M  9  311  392  468  1,574  1,650 
Net profit,   SEK M  7  227  288  342  1,159  1,213 
Earnings per   share, SEK  0.01  0.93  1.17  1.39  4.77  4.98 
Cash flow from   operating activities, SEK M  223  463  1,091  1,163  3,599  3,671 

* EBITA 1: EBITA before acquisition, restructuring and integration costs.

For further information, please contact:

Jeanette Hedén Carlsson
EVP Communications & Brand Management
Phone: +46 (0)10 335 1003
Email:
jeanette.hedencarlsson@getinge.com 

Lars Mattsson
Head of Investor Relations
Phone: +46 (0)10 335 0043
Email:
lars.mattsson@getinge.com 

This information is information that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on July 17, 2017.


About Getinge
Getinge is a global provider of innovative solutions for operating rooms, intensive care units, sterilization departments and for life science companies and institutions. Based on our firsthand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the everyday life for people - today and tomorrow.

Share: